查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1424966

皮肤替代品和替代品的全球市场：市场规模和份额分析（按产品、类别、应用和最终用户）、工业需求预测（截至 2030 年）

Skin Replacements and Substitutes Market Size and Share Analysis by Product, Class, Application, End User - Global Industry Demand Forecast to 2030
出版日期: | 出版商: Prescient & Strategic Intelligence | 英文 350 Pages | 商品交期: 2-3个工作天内

价格
简介目录

到 2030 年，全球皮肤替代品市场规模预计将达到 18.692 亿美元，2024 年至 2030 年复合年增长率为 7.0%。 这是由于越来越多的公民在外表上花更多的钱，烧伤的发生率不断增加，交通事故的发生率不断增加，预期寿命猛增，皮肤病和慢性病的患病率不断增加。 据世界卫生组织称，印度每年有近100万人遭受重度和中度烧伤。 印度的高残疾调整生命年是由多种原因造成的，其中包括烧伤。

对外在美的兴趣日益浓厚：

因慢性病或其他原因皮肤受损的人们越来越多地寻求治疗来改善外表。 此外，医学领域的技术创新已经提供了多种可用作皮肤替代品的产品，例如去细胞皮肤替代品。 在这些产品中，尼龙网充当真皮，硅胶膜充当表皮。 然后将其植入猪胶原蛋白中，并透过化学黏合黏附在伤口底部。

深度烧伤会破坏皮肤的两层（真皮和表皮）并使它们暴露于微生物，这可能导致感染和进一步的併发症。 因此，建议及时进行医疗指导和手术。 灭菌后，人造皮肤具有促进细胞激素和生长因子释放以再生受损组织的能力。 移植物的宽度、开口和连通孔应该适合新皮肤再生。

伤口护理诊所和医院持续占据市场主导地位：

伤口护理诊所和医院是最大的最终用户，因为它们拥有复杂烧伤病例所需的先进设备、专家、必要的药物和技术。 随着越来越多人患有皮肤病，到这些医疗中心的就诊的人数也在增加。 此外，由于手术后会造成严重伤口，因此此类皮肤更换手术通常是整个术后护理计画的一部分。

亚太地区的成长机会：

由于医疗领域的进步和对皮肤护理的高需求，北美在市场上占据主导地位。 此外，各大公司正在与医院、美容中心和伤口护理诊所合作，行销和开发皮肤替代品和替代品，目标是获得 FDA 批准。 例如，2021 年 6 月，Mallinckrodt Pharmaceuticals 的一款名为 StrataGraft 的新型皮肤产品获得 FDA 批准。 如果一些深层皮肤层和真皮成分在热烧伤后保持完整，则该产品可以减少自体移植的需要。

由于整容手术需求不断增长以及糖尿病足溃疡 (DFU) 等皮肤病的高发，亚太地区 (APAC) 成为成长最快的市场。 15-25% 的糖尿病患者会在某个时候出现 DFU。 据世界卫生组织称，中国糖尿病患者人数预计将从2016年的1.1亿增加到2040年的1.5亿人。 此外，2019 年至 2021 年间，印度新诊断出 3,100 万人患有糖尿病。

本报告分析了全球皮肤替代品和替代品市场，包括市场的基本结构和最新情况、主要推动和限制因素，以及全球、按地区和主要国家的市场规模趋势预测。（金额基础，2017 -2030），按产品、类别、应用程式和最终用户划分的详细趋势、当前市场竞争状况以及主要公司的概况进行了调查。

目录

第1章研究范围

第2章研究方法

第 3 章执行摘要

第 4 章市场指标

第5章产业展望

  • 市场动态
    • 趋势
    • 促进因素
    • 抑制因素/挑战
    • 促进/抑制因子影响分析
  • 新型冠状病毒感染 (COVID-19) 的影响
  • 波特五力分析

第6章世界市场

  • 摘要
  • 市场收入：依产品分类（2017-2030 年）
  • 市场收入：依类别划分（2017-2030 年）
    • I 类市场收入：按类型划分（2017-2030 年）
    • 第二类市场收入：依类型划分（2017-2030 年）
    • 第三类市场收入：依类型分类（2017-2030 年）
  • 市场收入：依应用分类（2017-2030 年）
  • 市场收入：以最终用户划分（2017-2030 年）
  • 市场收入：按地区划分（2017-2030 年）

第7章北美市场

  • 摘要
  • 市场收入：依产品分类（2017-2030 年）
  • 市场收入：依类别划分（2017-2030 年）
    • I 类市场收入：按类型划分（2017-2030 年）
    • 第二类市场收入：依类型划分（2017-2030 年）
    • 第三类市场收入：依类型划分（2017-2030 年）
  • 市场收入：依应用分类（2017-2030 年）
  • 市场收入：以最终用户划分（2017-2030 年）
  • 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第 11 章中东与非洲 (MEA) 市场

第12章美国市场

  • 摘要
  • 市场收入：依产品分类（2017-2030 年）
  • 市场收入：依类别划分（2017-2030 年）
    • I 类市场收入：按类型划分（2017-2030 年）
    • 第二类市场收入：依类型划分（2017-2030 年）
    • 第三类市场收入：依类型划分（2017-2030 年）
  • 市场收入：依应用分类（2017-2030 年）
  • 市场收入：以最终用户划分（2017-2030 年）

第13章加拿大市场

第14章德国市场

第15章法国市场

第16章英国市场

第17章义大利市场

第18章西班牙市场

第19章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

  • 市场参与者及其提供的产品/服务列表
  • 主要公司的竞争基准
  • 各大公司的产品基准
  • 近期策略发展状况

第30章公司简介

  • Acelity L.P. Inc.
  • MiMedx Group Inc.
  • Organogenesis Inc.
  • Vericel Corporation
  • FUJIFILM Cellular Dynamics Inc.
  • Smith & Nephew plc
  • Integra LifeSciences Holdings Corporation
  • AlloSource
  • MatTek Corporation

第31章 附录

简介目录
Product Code: 11704

The global skin replacements and substitutes market size is set to be USD 1,869.2 million by 2030, witnessing 7.0% CAGR between 2024 and 2030. This will be due to the increasing number of citizens spending on appearance enhancement, rising incidence of burns, growing rate of road accidents, surging life expectancy, and escalating prevalence of skin and chronic disease. As per the WHO, nearly 1 million people in India get severe and moderate burns each year. The high disability-adjusted life-years in India are due to burns and many other causes.

Increasing Focus on Enhance Appearance of Skin

People with skin damage due to chronic diseases and other reasons are increasingly seeking remedies to enhance their appearance. Further, due to the innovations in the healthcare sector, various products are available for use as skin replacement, such as acellular substitutes; these products are cost-effective and efficient. In these products, a nylon mesh works as the dermis, and a silicon membrane works as the epidermis. It is then implanted into porcine collagen and connected by chemical bonds for attachment to the wound base.

Deep burns can destroy both layers of the skin (dermis and epidermis), exposing them to microorganisms, which can cause infections and further complications. Therefore, quick medical guidance or surgery is advised. Artificial skin, after sterilization, has the capacity to enhance the release of cytokines and growth factors for regenerating the destroyed tissue. The width, orifice, and interconnecting pores of the graft should be ideal for the regeneration of new skin.

Continued Dominance of Wound Care Clinics and Hospitals on Market

Wound care clinics and hospitals are the largest end users as they have sophisticated facilities, expert professionals, necessary medication, and the technology required for complicated burn cases. With an increasing number of people suffering from dermatological diseases, the footfall at these healthcare centers is rising. Moreover, severe wounds are caused after surgery; hence, such skin replacement procedures are often part of the overall post-operative care regimen.

Growing Opportunities in APAC

North America is dominating the market due to the advancements in the healthcare sector and a high demand for skincare. Moreover, the key market players are collaborating with hospitals, cosmetic centers, and wound care clinics to sell and advance their skin replacement and substitute products and pursuing the approval of the FDA for them. For instance, in June 2021 Mallinckrodt Pharmaceuticals received the FDA approval for a novel skin product, called StrataGraft. It can reduce the requirement for autografts if some part of the deeper skin layers and dermal elements remains intact after a thermal burn injury.

APAC is the fastest-growing market due to the increasing demand for cosmetic procedures and the high prevalence of diabetic foot ulcers and other skin issues. Between 15 and 25% of the population with diabetes mellitus would develop a DFU at some point. As per the WHO, diabetic population in China is expected to reach 150 million by 2040 from 110 million in 2016. Moreover, India registered 31 million new diabetes diagnoses in 2019-2021.

Some of the key players in the skin and replacements and substitutes market are Acelity L.P. Inc., MiMedx Group Inc., Organogenesis Inc., Vericel Corporation, FUJIFILM Cellular Dynamics Inc., Smith & Nephew plc, Integra LifeSciences Holdings Corporation, AlloSource, and MatTek Corporation.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by product
    • 1.4.2. Market size breakdown, by class
    • 1.4.3. Market size breakdown, by application
    • 1.4.4. Market size breakdown, by end user
    • 1.4.5. Market size breakdown, by region
    • 1.4.6. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Product (2017-2030)
  • 6.3. Market Revenue, by Class (2017-2030)
    • 6.3.1. Class I market revenue, by type (2017-2030)
    • 6.3.2. Class II market revenue, by type (2017-2030)
    • 6.3.3. Class III market revenue, by type (2017-2030)
  • 6.4. Market Revenue, by Application (2017-2030)
  • 6.5. Market Revenue, by End User (2017-2030)
  • 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Product (2017-2030)
  • 7.3. Market Revenue, by Class (2017-2030)
    • 7.3.1. Class I market revenue, by type (2017-2030)
    • 7.3.2. Class II market revenue, by type (2017-2030)
    • 7.3.3. Class III market revenue, by type (2017-2030)
  • 7.4. Market Revenue, by Application (2017-2030)
  • 7.5. Market Revenue, by End User (2017-2030)
  • 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Product (2017-2030)
  • 8.3. Market Revenue, by Class (2017-2030)
    • 8.3.1. Class I market revenue, by type (2017-2030)
    • 8.3.2. Class II market revenue, by type (2017-2030)
    • 8.3.3. Class III market revenue, by type (2017-2030)
  • 8.4. Market Revenue, by Application (2017-2030)
  • 8.5. Market Revenue, by End User (2017-2030)
  • 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Product (2017-2030)
  • 9.3. Market Revenue, by Class (2017-2030)
    • 9.3.1. Class I market revenue, by type (2017-2030)
    • 9.3.2. Class II market revenue, by type (2017-2030)
    • 9.3.3. Class III market revenue, by type (2017-2030)
  • 9.4. Market Revenue, by Application (2017-2030)
  • 9.5. Market Revenue, by End User (2017-2030)
  • 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Product (2017-2030)
  • 10.3. Market Revenue, by Class (2017-2030)
    • 10.3.1. Class I market revenue, by type (2017-2030)
    • 10.3.2. Class II market revenue, by type (2017-2030)
    • 10.3.3. Class III market revenue, by type (2017-2030)
  • 10.4. Market Revenue, by Application (2017-2030)
  • 10.5. Market Revenue, by End User (2017-2030)
  • 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Product (2017-2030)
  • 11.3. Market Revenue, by Class (2017-2030)
    • 11.3.1. Class I market revenue, by type (2017-2030)
    • 11.3.2. Class II market revenue, by type (2017-2030)
    • 11.3.3. Class III market revenue, by type (2017-2030)
  • 11.4. Market Revenue, by Application (2017-2030)
  • 11.5. Market Revenue, by End User (2017-2030)
  • 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Product (2017-2030)
  • 12.3. Market Revenue, by Class (2017-2030)
    • 12.3.1. Class I market revenue, by type (2017-2030)
    • 12.3.2. Class II market revenue, by type (2017-2030)
    • 12.3.3. Class III market revenue, by type (2017-2030)
  • 12.4. Market Revenue, by Application (2017-2030)
  • 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Product (2017-2030)
  • 13.3. Market Revenue, by Class (2017-2030)
    • 13.3.1. Class I market revenue, by type (2017-2030)
    • 13.3.2. Class II market revenue, by type (2017-2030)
    • 13.3.3. Class III market revenue, by type (2017-2030)
  • 13.4. Market Revenue, by Application (2017-2030)
  • 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Product (2017-2030)
  • 14.3. Market Revenue, by Class (2017-2030)
    • 14.3.1. Class I market revenue, by type (2017-2030)
    • 14.3.2. Class II market revenue, by type (2017-2030)
    • 14.3.3. Class III market revenue, by type (2017-2030)
  • 14.4. Market Revenue, by Application (2017-2030)
  • 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Product (2017-2030)
  • 15.3. Market Revenue, by Class (2017-2030)
    • 15.3.1. Class I market revenue, by type (2017-2030)
    • 15.3.2. Class II market revenue, by type (2017-2030)
    • 15.3.3. Class III market revenue, by type (2017-2030)
  • 15.4. Market Revenue, by Application (2017-2030)
  • 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Product (2017-2030)
  • 16.3. Market Revenue, by Class (2017-2030)
    • 16.3.1. Class I market revenue, by type (2017-2030)
    • 16.3.2. Class II market revenue, by type (2017-2030)
    • 16.3.3. Class III market revenue, by type (2017-2030)
  • 16.4. Market Revenue, by Application (2017-2030)
  • 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Product (2017-2030)
  • 17.3. Market Revenue, by Class (2017-2030)
    • 17.3.1. Class I market revenue, by type (2017-2030)
    • 17.3.2. Class II market revenue, by type (2017-2030)
    • 17.3.3. Class III market revenue, by type (2017-2030)
  • 17.4. Market Revenue, by Application (2017-2030)
  • 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Product (2017-2030)
  • 18.3. Market Revenue, by Class (2017-2030)
    • 18.3.1. Class I market revenue, by type (2017-2030)
    • 18.3.2. Class II market revenue, by type (2017-2030)
    • 18.3.3. Class III market revenue, by type (2017-2030)
  • 18.4. Market Revenue, by Application (2017-2030)
  • 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Product (2017-2030)
  • 19.3. Market Revenue, by Class (2017-2030)
    • 19.3.1. Class I market revenue, by type (2017-2030)
    • 19.3.2. Class II market revenue, by type (2017-2030)
    • 19.3.3. Class III market revenue, by type (2017-2030)
  • 19.4. Market Revenue, by Application (2017-2030)
  • 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Product (2017-2030)
  • 20.3. Market Revenue, by Class (2017-2030)
    • 20.3.1. Class I market revenue, by type (2017-2030)
    • 20.3.2. Class II market revenue, by type (2017-2030)
    • 20.3.3. Class III market revenue, by type (2017-2030)
  • 20.4. Market Revenue, by Application (2017-2030)
  • 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Product (2017-2030)
  • 21.3. Market Revenue, by Class (2017-2030)
    • 21.3.1. Class I market revenue, by type (2017-2030)
    • 21.3.2. Class II market revenue, by type (2017-2030)
    • 21.3.3. Class III market revenue, by type (2017-2030)
  • 21.4. Market Revenue, by Application (2017-2030)
  • 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Product (2017-2030)
  • 22.3. Market Revenue, by Class (2017-2030)
    • 22.3.1. Class I market revenue, by type (2017-2030)
    • 22.3.2. Class II market revenue, by type (2017-2030)
    • 22.3.3. Class III market revenue, by type (2017-2030)
  • 22.4. Market Revenue, by Application (2017-2030)
  • 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Product (2017-2030)
  • 23.3. Market Revenue, by Class (2017-2030)
    • 23.3.1. Class I market revenue, by type (2017-2030)
    • 23.3.2. Class II market revenue, by type (2017-2030)
    • 23.3.3. Class III market revenue, by type (2017-2030)
  • 23.4. Market Revenue, by Application (2017-2030)
  • 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Product (2017-2030)
  • 24.3. Market Revenue, by Class (2017-2030)
    • 24.3.1. Class I market revenue, by type (2017-2030)
    • 24.3.2. Class II market revenue, by type (2017-2030)
    • 24.3.3. Class III market revenue, by type (2017-2030)
  • 24.4. Market Revenue, by Application (2017-2030)
  • 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Product (2017-2030)
  • 25.3. Market Revenue, by Class (2017-2030)
    • 25.3.1. Class I market revenue, by type (2017-2030)
    • 25.3.2. Class II market revenue, by type (2017-2030)
    • 25.3.3. Class III market revenue, by type (2017-2030)
  • 25.4. Market Revenue, by Application (2017-2030)
  • 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Product (2017-2030)
  • 26.3. Market Revenue, by Class (2017-2030)
    • 26.3.1. Class I market revenue, by type (2017-2030)
    • 26.3.2. Class II market revenue, by type (2017-2030)
    • 26.3.3. Class III market revenue, by type (2017-2030)
  • 26.4. Market Revenue, by Application (2017-2030)
  • 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Product (2017-2030)
  • 27.3. Market Revenue, by Class (2017-2030)
    • 27.3.1. Class I market revenue, by type (2017-2030)
    • 27.3.2. Class II market revenue, by type (2017-2030)
    • 27.3.3. Class III market revenue, by type (2017-2030)
  • 27.4. Market Revenue, by Application (2017-2030)
  • 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Product (2017-2030)
  • 28.3. Market Revenue, by Class (2017-2030)
    • 28.3.1. Class I market revenue, by type (2017-2030)
    • 28.3.2. Class II market revenue, by type (2017-2030)
    • 28.3.3. Class III market revenue, by type (2017-2030)
  • 28.4. Market Revenue, by Application (2017-2030)
  • 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. Acelity L.P. Inc.
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. MiMedx Group Inc.
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Organogenesis Inc.
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. Vericel Corporation
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. FUJIFILM Cellular Dynamics Inc.
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. Smith & Nephew plc
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. Integra LifeSciences Holdings Corporation
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. AlloSource
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. MatTek Corporation
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports